Idicitinib Monotherapy for Low-Risk GVHD

Idicitinib had a favorable safety profile with a low incidence of grade III or higher non hematologic and noninfectious adverse events. There were no significant differences between the two groups at one year in terms of the rates of non-relapse mortality, relapse, chronic GVHD, or survival. Based on these findings, the authors concluded that Idicitinib monotherapy is a safe and effective alternative to systemic glucocorticoids for low-risk GVHD.